← Russell 3000 cross-section

EXEL EXELIXIS, INC.

Trailing twelve months to 2026-07-03 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$13.8bn
Revenue TTM
$2.4bn
Net income TTM
$861m
Free cash flow
$1.2bn
Composite score
77.1
Sector rank
#575

Valuation

P / E
16.0
EV / EBITDA
12.9
EV / sales
5.3
FCF yield
8.52%
Earnings yield vs 10-yr
1.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
35.3%
EBITDA margin
41.0%
ROE
46.7%
ROIC
96.7%
Revenue growth
9.2%

Insider activity, last 90 days

Net open-market
$-1.22m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The increases in sales volume were largely driven by refills, reflecting the longer duration of therapy for the combination of CABOMETYX with nivolumab, and increases in related market share reflecting the continued evolution of the metastatic RCC and NET treatment landscapes. The increases in the amount of discounts and allowances for the three and six months ended June 30, 2026 , as compared to the corresponding prior year periods, were primarily the result of increases in the volume of units sold, higher utilization, and higher discounts associated with the Part D Discount Program, partially offset by lower utilization under the 340B Drug Pricing Program. …EXELIXIS, INC., 10-Q, period ended 2026-07-03, filed 2026-08-05

Read the full passage →